Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
If you are researching cancer immune cell therapy in Japan, one of the first practical questions is usually about money: will my insurance pay for it? For NK (natural killer) cell therapy, the short answer is that it is provided as a self-pay treatment, which means it is not covered by Japan’s public health insurance. This article explains what that means in practice, why it matters for international patients, and which questions are worth raising with a doctor before you make any decision.
The short answer: NK cell therapy is a self-pay treatment
At Grand Green Osaka Umekita Clinic, NK cell therapy is offered as a self-pay (not covered by insurance) treatment. In Japan, this is often called jiyu shinryo. It means the cost is paid by the patient directly rather than being billed to the national insurance system. It also means that the treatment is separate from the standard care that is usually reimbursed, such as surgery, chemotherapy, or radiation therapy.
Self-pay does not automatically say anything good or bad about a treatment. It simply describes how the care is financed and regulated. However, it is a reminder that you should look carefully at what is being offered, what is known and not known about it, and how it fits alongside the treatment you are already receiving.
Why self-pay matters for international patients
Many international patients are used to health systems where an oncologist refers them to a therapy and an insurer then decides whether to cover it. In Japan, treatments that are not covered by public insurance are handled differently. The clinic explains the treatment, the patient agrees to it after consultation, and the patient pays directly.
If you live outside Japan, there are a few additional points to keep in mind:
- Your home country’s insurance or travel insurance may not reimburse treatment received in Japan, so it is wise to ask your insurer before you travel.
- Self-pay treatments are normally not part of an insurance-based cost cap, so you should ask for a clear explanation of what the fee covers and when it is paid.
- Because the treatment is outside the standard insurance framework, your own oncologist may want to review the plan with you. Clear documents in English can help that conversation.
How the treatment is regulated in Japan
Being self-pay does not mean being unregulated. Cell-based therapies of this kind are provided in Japan under the Act on the Safety of Regenerative Medicine. Under this law, a clinic submits a treatment plan that is reviewed by a certified committee and accepted by the Ministry of Health, Labour and Welfare before it can offer the therapy. Cell culture and processing are carried out at licensed facilities.
For a patient, the useful point is that you can ask the clinic about this framework. A trustworthy clinic should be able to explain which plan covers the therapy, where the cells are processed, and how safety is monitored. Acceptance of a plan is a statement about the procedures and safety management, not a guarantee that the treatment will work for any individual person.
What NK cell therapy involves, and what it cannot promise
NK cells are a type of immune cell that can recognize and attack abnormal cells, including cancer cells and virus-infected cells. In NK cell therapy, cells are collected from a standard blood draw, activated and expanded at a specialized facility, and then returned to the body by intravenous infusion. Because the cells come from your own body, the risk of rejection is considered low, although temporary effects such as fever or fatigue may occur.
It is important to be realistic. Research on immune cell therapies, including NK cells, is ongoing, and results differ between cancer types, disease stages, and individual patients. NK cell therapy is not a replacement for standard cancer treatment, and it should not be presented as a cure. Its role, if appropriate for you, is usually discussed as something that may be considered alongside standard care or after treatment has finished, with the aim of supporting immune function. Whether it is suitable depends on a doctor’s assessment of your situation.
Questions to ask before you decide
Because the treatment is self-pay, it helps to prepare a list of questions in advance. A consultation is the right place to ask them, and a good clinic will welcome careful questions. Consider asking about the following:
- Is NK cell therapy appropriate for my type and stage of cancer, or for my goal of recurrence prevention?
- How will it fit with the surgery, chemotherapy, or radiation that I am receiving or have already received?
- What are the total costs, including the consultation, blood draw, cell processing, and each infusion, and how are they explained in writing?
- What risks and side effects are possible, and who should I contact if I feel unwell after returning home?
- What information can be shared with my own doctor abroad, and in which language?
The clinic’s English information page and the contact option for international patients on the website are designed to help overseas patients begin this process. Fees, number of sessions, risks, and eligibility are confirmed by the doctor at the consultation, so please treat any general article, including this one, as background rather than personal medical advice.
Planning with your own doctors in mind
The most helpful approach is to keep your existing medical team involved. Standard treatments have the strongest evidence for most cancers, and they should not be delayed or stopped because of an interest in a self-pay option. Grand Green Osaka Umekita Clinic can coordinate with the institution providing your standard treatment, and sharing your medical records in advance can make a first consultation in Osaka more productive.
It can also help to separate the questions in your mind. One is whether NK cell therapy is medically reasonable for you. Another is whether the cost and the travel are manageable for you and your family. A third is whether you feel you have received enough information to give informed consent. Taking time over each of these is normal, and you are not required to decide on the day of your first conversation.
Key takeaways
NK cell therapy in Japan is a self-pay treatment, outside the public insurance system, and it is provided under the regenerative medicine law with specific safety procedures. It uses your own cells, can be considered alongside standard care, and does not promise a particular outcome. If you are an international patient in Osaka or planning a visit, prepare questions about suitability, costs, risks, and coordination with your own doctors, and ask your insurer what it will and will not reimburse. A careful, unhurried consultation with a doctor is the best next step.
- Self-pay treatmentNot covered by public insurance
- Japanese law frameworkSafety management under the law
- Alongside standard careNot a replacement
- Doctor consultationCosts, risks, suitability
This figure is a conceptual diagram summarizing the article
References
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.